Furiex Reports Second Quarter 2013 Financial Results

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended June 30, 2013.

Total revenues were $3.0 million for the quarter ended June 30, 2013, compared to $13.1 million for the same period in the prior year. The primary driver of the decrease was the fact that in May 2012 the Company recorded a $10.0 million regulatory milestone payment from Takeda with respect to the acceptance of the submission of a Marketing Authorization Application from the European Medicines Agency for alogliptin.

Furiex recorded second quarter royalty revenue of $3.0 million, compared to $3.1 million for the same period in the prior year. Royalty revenue included royalties related to Nesina and Liovel ® sales in Japan, and Priligy sales in various countries outside of the United States.

Research and development expenses were $22.1 million for the quarter ended June 30, 2013, compared to $30.8 million for the same period in the prior year. The level of research and development expense during the current quarter relates primarily to the clinical trial and manufacturing costs associated with the continued development of eluxadoline. The level of quarterly research and development costs, including drug manufacture, patient recruitment, clinical monitoring and related pass-through costs, can vary significantly from quarter to quarter based on the timing of specific activities associated with the on-going Phase I and Phase III clinical trials for eluxadoline.

Second quarter selling, general and administrative expenses were $3.2 million for 2013, compared to $2.8 million for the same period in the prior year. The change in selling, general and administrative expenses for the quarter was due primarily to fluctuations in non-cash stock compensation expense, including the mark-to-market adjustment for non-vested consultant options.

Interest expense of $1.1 million for the quarter ended June 30, 2013 related entirely to our loan agreement with MidCap Funding III, LLC, Midcap Funding RE Holdings, LLC and Silicon Valley Bank.

Net loss was $23.5 million for the second quarter of 2013, compared to net loss of $20.8 million for the second quarter of 2012. The changes in net loss during the second quarter of 2013, as compared to the same period in the prior year, relates primarily to the changes in revenues and expenses previously discussed.

Net loss per basic and diluted share for the second quarter of 2013 was $2.32, compared to net loss per basic and diluted share of $2.09 for the second quarter of 2012.

“We’re pleased to have completed enrollment of the Phase III program for eluxadoline in July and expect to have top line results of the efficacy endpoints for these studies in the first quarter of 2014,” said June Almenoff, M.D., Ph.D., president and chief medical officer of Furiex, “The Phase I studies and manufacturing work supporting the New Drug Application remain on schedule.”

Fred Eshelman, Pharm.D., chairman of Furiex, added, “The U.S. launch of Nesina, Kazano ® and Oseni ® on June 17, 2013, the positive CHMP opinion on the alogliptin family of products and the recent marketing authorization from the CFDA, we believe, will add value to the alogliptin franchise and continue to provide an important foundation for our business. We remain on track with the development of eluxadoline and we are one step closer to our goal of filing a New Drug Application with patient enrollment in the Phase III clinical trials now complete.”

Furiex will conduct a live conference call and webcast Wednesday, August 7, 2013, at 9:00 a.m. ET to discuss its second quarter 2013 results and financial outlook for 2013 as well as provide an overview of its business and pipeline. A Q&A session will follow. All interested parties can access the webcast through the Presentations & Events link in the Investors section of the Furiex website at www.furiex.com. The webcast will be archived shortly after the call for on-demand replay. The conference call will be broadcast live over the Internet and will also be available using the following direct dial numbers:
Participant dial-in:       +1.877.677.9122 (U.S./Canada)
+1.708.290.1401 (International)
Conference ID: 11013047

About Furiex

Furiex Pharmaceuticals is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of drug development programs by advancing them through the drug discovery and development process in a cost-efficient manner. Our drug development programs are designed and driven by a core team with extensive drug development experience. The Company collaborates with pharmaceutical and biotechnology companies and has a diversified product portfolio and pipeline with multiple therapeutic candidates, including one Phase III-ready asset, two compounds in Phase III development, one of which is with a partner, and four products on the market. The Company's mission is to develop innovative medicines faster and at a lower cost, thereby improving profitability and accelerating time to market while providing life-improving therapies for patients. For more information, visit www.furiex.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although Furiex attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause actual results to differ materially include the following: continuing losses and our potential need for additional financing; the risks and expense of continuing the research and development activities of our existing compounds; the risk of finding a collaborator for our late-stage compounds; progress of compounds in clinical trials and regulatory approvals as it relates to receiving future milestone payments; inability of our existing collaborators to effectively market approved products for which we receive royalty and sales-based milestone payments; changes in the safety and efficacy profile of our existing compounds as they progress through research and development; potential changes to regulatory guidance by regulatory agencies such as the U.S. Food and Drug Administration and the European Medicines Agency; new collaborative agreements that we might enter into in the future; the costs of defending any patent opposition or litigation necessary to protect our proprietary technologies; and the other risk factors set forth from time to time in the SEC filings for Furiex, copies of which can be found on our website.

1 United States Adopted Names Council (USAN) adopted, International Nonproprietary Names (INN) approval pending.
(In thousands, except per share data)
Three Months Ended Six Months Ended
June 30,

June 30,
2012   2013   2012   2013  
Milestones $ 10,000 $ $ 10,000 $ 30,000
Royalties       3,075         2,990         5,720         12,315  
Total revenue       13,075         2,990         15,720         42,315  
Research and development expenses 30,753 22,050 40,121 47,414
Selling, general and administrative expenses 2,790 3,236 5,523 7,109
Depreciation and amortization       21         19         42         42  
Total operating expenses       33,564         25,305         45,686         54,565  
Operating loss (20,489 ) (22,315 ) (29,966 ) (12,250 )
Interest expense 274 1,111 549 2,211
Other income, net               2                 93  
Loss before provision for income taxes (20,763 ) (23,424 ) (30,515 ) (14,368 )
Provision for income taxes       6         29         12         121  
Net loss $     (20,769 ) $     (23,453 ) $     (30,527 ) $     (14,489 )
Net loss per basic and diluted share $     (2.09 ) $     (2.32 ) $     (3.07 ) $     (1.44 )
Weighted-average shares used to compute net loss per basic and diluted share 9,957 10,119 9,953 10,078
(In thousands, except share data)
December 31, June 30,
2012 2013
Current assets:
Cash and cash equivalents $ 25,718 $ 27,646
Accounts receivable, net 11,745 3,162
Prepaid expenses   320       79  
Total current assets 37,783 30,887
Property and equipment, net 118 102
Investments 7,500 7,500
Goodwill 49,116 49,116
Other assets   238       163  
Total assets $ 94,755   $   87,768  
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable $ 6,604 $ 11,655
Accrued expenses 10,230 7,049
Current portion of long-term debt   5,405       11,892  
Total current liabilities 22,239 30,596
Long-term debt, net 34,595 28,108
Other long-term liabilities   324       460  
Total liabilities   57,158       59,164  

Common stock, $0.001 par value, 40,000,000 shares authorized; 10,015,297 and

10,273,224 shares issued and outstanding, respectively
10 10

Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued or

Paid-in capital 164,577 170,073
Accumulated deficit   (126,990 )     (141,479 )
Total shareholders’ equity   37,597       28,604  
Total liabilities and shareholders’ equity $ 94,755 $   87,768  

Copyright Business Wire 2010